Influence of enalapril, quinapril and losartan on lipopolysaccharide (LPS)-induced serum concentrations of TNF-α, IL-1β, IL-6 in spontaneously hypertensive rats (SHR)

Pharmacological Reports

Volumn 59, Issue 4, 2007, Pages 437-446

  Andrzejczak, Dariusz ^a   Górska, Dorota ^a   Czarnecka, Elzbieta ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Enalapril; Losartan; Proinflammatory cytokine; Quinapril; SHR

Indexed keywords

CHOLESTEROL; ENALAPRIL; ETHER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; LOSARTAN; METHYLCELLULOSE; QUINAPRIL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE RELEASE; DIASTOLIC BLOOD PRESSURE; DRUG SELECTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HYPERTENSION; IMMUNOMODULATION; MALE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

EID: 35048831743     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Alberti KGMM, Zimmet P, Shaw J: Metabolic syndrome - a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med, 2006, 23, 469-480.
2. Alexander BT, Cockrell KL, Massey MB, Bennett WA, Granger JP: Tumor necrosis factor-alpha-induced hypertension in pregnant rats results in decreased renal neuronal nitric oxide synthase expression. Am J Hypertens, 2002, 15, 170-175.
3. Andrzejczak D, Górska D, Czarnecka E: Influence of amlodipine and atenolol on lipopolysaccharide (LPS)-induced serum concentrations of TNF-α, IL-1β, IL-6 in spontaneously hypertensive rats (SHR). Pharmacol Rep, 2006, 58, 711-719.
4. Bachetti T, Comini L, Pasini E, Cargnoni A, Curello S, Ferrari R: ACE-inhibition with quinapril modulates the nitric oxide pathway in normotensive rats. J Mol Cell Cardiol, 2001, 33, 395-403.
5. Bautista LE, Vera LM, Arenas IA, Gamarra G: Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-α) and essential hypertension. J Hum Hypertens, 2005, 19, 149-154.
6. Blanco S, Vaquero M, Gomez-Guerrero C, Lopez D, Egido J, Romero R: Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension. Am J Hypertens, 2005, 18, 557-565.
7. Brasier AR, Li J, Wimbish KA: Tumor necrosis factor activates angiotensinogen gene expression by the Rel A transactivator. Hypertension, 1996, 27, 1009-1017.
8. Campese VM, Ye S, Zhong H: Downregulation of neuronal nitric oxide synthase and interleukin-1beta mediates angiotensin II-dependent stimulation of sympathetic nerve activity. Hypertension, 2002, 39, 519-524.
9. Chae CU, Lee RT, Rifai N, Ridker PM: Blood pressure and inflammation in apparently healthy men. Hypertension, 2001, 38, 399-403.
10. Chłopicki S, Gryglewski RJ: Angiotensin converting enzyme (ACE) and hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitors in the forefront of pharmacology of endothelium. Pharmacol Rep, 2005, 57, Suppl, 86-96.
11. Chrysohoou C, Pitsavos C, Panagiotakos DB, Skoumas J, Stefanadis C: Association between prehypertension status and inflammatory markers related to atherosclerotic disease. Am J Hypertens, 2004, 171,568-573.
12. Cominacini L, Pasini A, Garbin U, Evangelista S, Crea AE, Tagliacozzi D, Nava C et al.: Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species. Am J Hypertens, 2002, 15, 891-895.
13. Conrad KP, Miles TM, Benyo DF: Circulating levels of immunoreactive cytokines in women with preeclampsia. Am J Reprod Immunol, 1998, 40, 102-111.
14. Cottone S, Vadala A, Vella MC, Nardi E, Mule G, Contorno A, Riccobene R et al.: Changes of plasma endothelin and growth factor levels, and of left ventricular mass, after chronic AT1-receptor blockade in human hypertension. Am J Hypertens, 1998, 11, 548-553.
15. Dalbeth N, Edwards J, Fairchild S, Callan M, Hall FC: The non-thiol angiotensin-converting enzyme inhibitor quinapril suppresses inflammatory arthritis. Rheumatology, 2005, 44, 24-31.
16. Dalekos GN, Elisaf M, Bairaktari E, Tsolas O, Siamopoulos KC: Ipcreased serum levels of interleukin-1 beta in the systemic circulation of patients with essential hypertension: additional risk factor for atherogenesis in hypertensive patients? J Lab Clin Med, 1997, 129, 300-308.
17. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R: Metabolic syndrome: A comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circ Res, 2005, 111, 1448-1454.
18. Dredge K, Connor TJ, Kelly JP, Leonard BE: Differential effect of a single high dose of the tricyclic antidepressant imipramine on interleukin-1β and tumor necrosis factor-α secretion following an in vivo lipopolysaccharide challenge in rats. Int J Immunopharmacol, 1999, 21, 663-673.
19. Dzielak DJ: The immune system and hypertension. Hypertension, 1992, 19, Suppl 1, 136-144.
20. Gardiner SM, Kemp PA, March JE, Woolley J, Bennett T: The influence of antibodies to TNF-alpha and IL-1beta on haemodynamic responses to the cytokines, and to lipopolysaccharide, in conscious rats. Br J Pharmacol, 1998, 125, 1543-1550.
21. Gullestad L, Aukrust P, Ueland T, Espevik T, Yee G, Vagelos R, Frøland SS et al.: Effect of high-versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol, 1999, 34, 2061-2067.
22. Gurlek A, Kilickap M, Dincer I, Dandachi R, Tutkak H, Oral D: Effect of losartan on circulating TNFalpha levels and left ventricular systolic performance in patients with heart failure. J Cardiovasc Risk, 2001, 8, 279-282.
23. Han Y, Runge MS, Brasier AR: Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors. Circ Res, 1999, 84, 695-703.
24. Iiyama K, Nagano M, Yo Y, Nagano N, Kamide K, Higaki J, Mikami H et al.: Impaired endothelial function with essential hypertension assessed by ultrasonography. Am Heart J, 1996, 132, 779-782.
25. Ikeda U, Ikeda M, Oohara T, Oguchi A, Kamitani T, Tsuruya Y, Kano S: Interleukin 6 stimulates growth of vascular smooth muscle cells in a PDGF-dependent manner. Am J Physiol, 1991, 260, H1713-H1717.
26. Inokuchi Y, Morohashi T, Kawana I, Nagashima Y, Kihara M, Umemura S: Amelioration of 2,4,6-trinitro-benzene sulphonic acid induced colitis in angiotensinogen gene knockout mice. Gut, 2005, 54, 349-356.
27. Kannan H, Tanaka Y, Kunitake T, Ueta Y, Hayashida Y, Yamashita H: Activation of sympathetic outflow by recombinant human interleukin-1 beta in conscious rats. Am J Physiol, 1996, 270, R479-R485.
28. Kasiske BL, Ma JZ, Kalil RSN, Louis TA: Effects of antihypertensive therapy on serum lipids. Ann Intern Med, 1995, 122, 133-141.
29. Kher N, Marsh JD: Pathobiology of atherosclerosis - a brief review. Semin Thromb Hemost, 2004, 30, 665-672.
30. Kimura T, Yamamoto T, Ota K, Shoji M, Inoue M, Sato K, Ohta M et al.: Central effects of interleukin-1 on blood pressure, thermogenesis, and the release of vasopressin, ACTH, and atrial natriuretic peptide. Ann N Y Acad Sci, 1993, 689, 330-345.
31. Kranzhöfer R, Schmidt J, Pfeiffer CAH, Hagl S, Libby P, Kübler W: Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol, 1999, 19, 1623-1629.
32. Lee DL, Sturgis LC, Labazi H, Osborne JB Jr., Fleming C, Pollock JS, Manhiani M et al.: Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. Am J Physiol Heart Circ Physiol, 2006, 290, H935-H940.
33. Li JJ: Inflammation in hypertension: primary evidence. Chin Med J (Engl), 2006, 119, 1215-1221.
34. Lindmark E, Siegbahn A: Tissue factor regulation and cytokine expression in monocyte-endothelial cell co-cultures: effects of a statin, an ACE-inhibitor and a low-molecular-weight heparin. Thromb Res, 2002, 108, 77-84.
35. Mehra VC, Ramgolam VS, Bender JR: Cytokines and cardiovascular disease. J Leukoc Biol, 2005, 78, 805-818.
36. Miyoshi M, Nagata K, Imoto T, Goto O, Ishida A, Watanabe T: ANG II is involved in the LPS-induced production of proinflammatory cytokines in dehydrated rats. Am J Physiol Regul Integr Comp Physiol, 2003, 284, R1092-R1097.
37. Morimoto K, Morimoto A, Nakamori T, Tan N, Minagawa T, Murakami N: Cardiovascular responses induced in free-moving rats by immune cytokines. J Physiol, 1992, 448, 307-320.
38. Niimi F, Nakamura A, Yanagawa Y: Suppression of endotoxin-induced renal tumor necrosis factor-alpha and interleukin-6 mRNA by renin-angiotensin system inhibitors. Jpn J Pharmacol, 2002, 88, 139-145.
39. Nishida K, Harrison DG, Navas JP, Fisher AA, Dockery SP, Uematsu M, Nerem RM et al.: Molecular cloning and characterization of the constitutive bovine aortic endothelial cell nitric oxide synthase. J Clin Invest, 1992, 90, 2092-2096.
40. Oksa A, Gajdos M, Fedelesova V, Sonstova V, Dzurik R: Effects of angiotensin-converting enzyme inhibitors on glucose and lipid metabolism in essential hypertension. J Cardiovasc Pharmacol, 1994, 23, 79-86,
41. Oparil S, Zaman MA, Calhoun DA: Pathogenesis of hypertension. Ann Intern, Med, 2003, 139, 761-776.
42. Orshal JM, Khalil RA: Interleukin-6 impairs endothelium-dependent NO-cGMT-mediated relaxation and enhances contraction in systemic vessels of pregnant rats. Am J Physiol Regul Integr Comp Physiol, 2004, 286, R1013-R1023.
43. Ortiz LA, Champion HC, Lasky JA, Gambelli F, Gozal E, Hoyle GW, Beasley MB et al.: Enalapril protects mice from pulmonary hypertension by inhibiting TNF-mediated activation of NF-kappaB,and AP-1. Am J Physiol Lung Cell Mol Physiol, 2002, 282, L1209-1221.
44. Panza JA, Quyyumi AA, Brush JE Jr., Epstein SE: Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med, 1990, 323, 22-27.
45. Pauletto P, Rattazzi M: Inflammation and hypertension: the search for a link. Nephrol Dial Transplant, 2006, 21, 850-853.
46. Peeters ACTM, Netea MG, Janssen MCH, Kullberg BJ, Van der Meer JWM, Thien T: Pro-inflammatory cytokines in patients with essential hypertension. Eur J Clin Invest, 2001, 31, 31-36.
47. Peeters ACTM, Netea MG, Kullberg BJ, Thien T, van der Meer JWM: The effect of renin-angiotensin system inhibitors on pro- and anti-inflammatory cytokine production. Immunology, 1998, 94, 376-379.
48. Qin J, Zhang Z, Liu J. Sun L, Hu L, Cooper ME, Cao Z: Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes. Kidney Int, 2003, 64, 565-571.
49. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med, 1999, 340, 115-126.
50. Sakemi T, Baba N, Yoshikawa Y: Angiotensin-converting enzyme inhibition attenuates hypercholes-terolemia and glomerular injury in hyperlipidemic Imai rats. Nephron, 1992, 62, 315-321.
51. Sanz-Rosa D, Oubiňa MP, Cediel E, de Las Heras N, Vegazo O, Jiménez J, Lahera V et al.: Effect of AT1 receptor antagonism on vascular and circulating inflammatory mediators in SHR: role of NF-kappaB/IkappaB system. Am J Physiol Heart Circ Physiol, 2005, 288, H111-H115.
52. Sardo MA, Castaldo M, Cinquegrani M, Bonaiuto M, Fontana L, Campo S, Campo GM et al.: Effects of AT1 receptor antagonist losartan on sICAM-1 and TNF-α levels in uncomplicated hypertensive patients. Angiology, 2004, 55, 195-203.
53. Schindler R, Dinarello CA, Koch KM: Angiotensin-converting-enzyme inhibitors suppress synthesis of tumour necrosis factor and interleukin 1 by human peripheral blood mononuclear cells. Cytokine, 1995, 7, 526-533.
54. Skurk T, van Harmelen V, Hauner H: Angiotensin II stimulates the release of interleukin-6 and interleukin-8 from cultured human adipocytes by activation of NF-κB. Arterioscler Thromb Vasc Biol, 2004, 24, 1199-1203.
55. Takahashi H, Nishimura M, Sakamoto M, Ikegaki I, Nakanishi T, Yoshimura M: Effects of interleukin-1 beta on blood pressure, sympathetic nerve activity, and pituitary endocrine functions in anesthetized rats. Am J Hypertens, 1992, 5, 224-229.
56. Takano M, Itoh N, Yayama K, Yamano M, Ohtani R, Okamoto H: Interleukin-6 as a mediator responsible for inflammation-induced increase in plasma angiotensinogen. Biochem Pharmacol, 1993, 45, 201-206.
57. Tikiz C, Utuk O, Pirildar T, Bayturan O, Bayindir P, Taneli F, Tikiz H et al.: Effects of angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis. J Rheumatol, 2005, 32, 2095-2101.
58. Ufnal M, Dudek M, Zera T, Szczepanska-Sadowska E: Centrally administered interleukin-1 beta sensitizes to the central pressor action of angiotensin II. Brain Res, 2006, 1100, 64-72.
59. Wassmann S, Stumpf M, Strehlow Y, Schmid A, Schieffer B, Böhm M, Nickenig G: Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res, 2004, 94, 534-541.
60. Wei GC, Sirois MG, Qu R, Liu P, Rouleau JL: Effects of quinapril on myocardial function, ventricular remodeling and cardiac cytokine expression in congestive heart failure in the rat. Cardiovasc Drugs-Ther, 2002, 16, 29-36.
61. Weinberg JR, Wright DJ, Guz A: Interleukin-1 and tumour necrosis factor cause hypotension in the conscious rabbit. Clin Sci (Lond), 1988, 75, 251-255.
62. Wisse BE: The inflammatory syndrome: The role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol, 2004, 15, 2792-2800.
63. Ye S, Mozayeni P, Gamburd M, Zhong H, Campese VM: Interleukin-1β and neurogenic control of blood pressure in normal rats and rats with chronic renal failure. Am J Physiol Heart Circ Physiol, 2000, 279, H2786-H2796.
64. Yoshizumi M, Perrella MA, Burnett JC Jr., Lee ME: Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res, 1993, 73, 205-209.